Nearly half of evaluable patients in the trial have achieved a best response of stable disease (SD) or better, including two
partial responses (PR) according to RECIST (Response Evaluation Criteria in Solid Tumors) guidelines.
Two patients with ovarian cancer achieved a
partial response based on reduction in the levels of the tumor marker CA-125.
Of these, 14 patients (78 percent) achieved a response of stable disease or better (10 to 38 weeks), including 3 unconfirmed
partial responses according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria.
At week 16, eight percent of patients (3/39) demonstrated a
partial response, 21 percent (8/39) had stable disease and 49 percent (19/39) had disease progression.
All three patients with stable disease and one of the patients with a
partial response are still receiving their first course of SGN-30 therapy.
A complete response rate of 9% and a
partial response rate of 8% were observed in the Dacogen arm.
